Apogee Therapeutics Inc. (APGE)
(Real Time Quote from BATS)
$50.87 USD
+0.68 (1.35%)
Updated Jul 23, 2024 03:26 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Balance Sheet
Fiscal Year End for Apogee Therapeutics Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 395 | 152 | -99,999 | -99,999 | -99,999 |
Receivables | 0 | 0 | NA | NA | NA |
Notes Receivable | 0 | 0 | NA | NA | NA |
Inventories | 0 | 0 | NA | NA | NA |
Other Current Assets | 3 | 0 | NA | NA | NA |
Total Current Assets | 398 | 152 | NA | NA | NA |
Net Property & Equipment | 0 | 0 | NA | NA | NA |
Investments & Advances | 0 | 0 | NA | NA | NA |
Other Non-Current Assets | 0 | 0 | NA | NA | NA |
Deferred Charges | 0 | 0 | NA | NA | NA |
Intangibles | 0 | 0 | NA | NA | NA |
Deposits & Other Assets | 0 | 0 | NA | NA | NA |
Total Assets | 401 | 152 | NA | NA | NA |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | NA | NA | NA |
Accounts Payable | 2 | 0 | NA | NA | NA |
Current Portion Long-Term Debt | 0 | 0 | NA | NA | NA |
Current Portion Capital Leases | 0 | 0 | NA | NA | NA |
Accrued Expenses | 17 | 10 | NA | NA | NA |
Income Taxes Payable | 0 | 0 | NA | NA | NA |
Other Current Liabilities | 0 | 0 | NA | NA | NA |
Total Current Liabilities | 21 | 10 | NA | NA | NA |
Mortgages | 0 | 0 | NA | NA | NA |
Deferred Taxes/Income | 0 | 0 | NA | NA | NA |
Convertible Debt | 0 | 0 | NA | NA | NA |
Long-Term Debt | 0 | 0 | NA | NA | NA |
Non-Current Capital Leases | 0 | 0 | NA | NA | NA |
Other Non-Current Liabilities | 0 | 0 | NA | NA | NA |
Minority Interest (Liabilities) | 0 | 0 | NA | NA | NA |
Total Liabilities | 21 | 10 | NA | NA | NA |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 177 | NA | NA | NA |
Common Stock (Par) | 0 | 4 | NA | NA | NA |
Capital Surplus | 503 | 0 | NA | NA | NA |
Retained Earnings | -124 | -40 | NA | NA | NA |
Other Equity | 0 | 0 | NA | NA | NA |
Treasury Stock | 0 | 0 | NA | NA | NA |
Total Shareholder's Equity | 380 | 142 | NA | NA | NA |
Total Liabilities & Shareholder's Equity | 401 | 152 | NA | NA | NA |
Total Common Equity | 380 | -35 | 0 | 0 | 0 |
Shares Outstanding | 50.60 | NA | NA | NA | NA |
Book Value Per Share | 7.51 | 0.00 | 0.00 | 0.00 | 0.00 |
Fiscal Year End for Apogee Therapeutics Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 816 | 395 | 423 | 125 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 4 | 3 | 4 | 6 |
Total Current Assets | NA | 821 | 398 | 426 | 131 |
Net Property & Equipment | NA | 1 | 0 | 0 | 0 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 824 | 401 | 426 | 131 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 4 | 2 | 1 | 11 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 16 | 17 | 16 | 6 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 22 | 21 | 17 | 18 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 22 | 21 | 17 | 18 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 177 |
Common Stock (Par) | NA | 0 | 0 | 0 | 7 |
Capital Surplus | NA | 958 | 503 | 501 | 0 |
Retained Earnings | NA | -156 | -124 | -92 | -71 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 801 | 380 | 409 | 113 |
Total Liabilities & Shareholder's Equity | NA | 824 | 401 | 426 | 131 |
Total Common Equity | 0 | 801 | 380 | 409 | -64 |
Shares Outstanding | 58.40 | 58.40 | 50.60 | 50.60 | 47.60 |
Book Value Per Share | 0.00 | 13.72 | 7.51 | 8.09 | -1.35 |